Renaissance Technologies LLC Raises Stock Position in CryoPort, Inc. $CYRX

Renaissance Technologies LLC lifted its position in CryoPort, Inc. (NASDAQ:CYRX) by 62.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 368,110 shares of the company’s stock after purchasing an additional 142,070 shares during the period. Renaissance Technologies LLC’s holdings in CryoPort were worth $3,048,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of CYRX. LPL Financial LLC lifted its holdings in shares of CryoPort by 6.6% in the 4th quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock worth $224,000 after buying an additional 1,433 shares during the period. The Manufacturers Life Insurance Company lifted its stake in CryoPort by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after acquiring an additional 1,557 shares during the period. State of Wyoming lifted its stake in CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after acquiring an additional 3,301 shares during the period. Basepoint Wealth LLC bought a new position in CryoPort during the 4th quarter worth about $34,000. Finally, BNP Paribas Financial Markets increased its position in CryoPort by 55.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock valued at $113,000 after purchasing an additional 4,225 shares during the period. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at CryoPort

In other CryoPort news, CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the transaction, the chief financial officer owned 109,850 shares in the company, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Edward J. Zecchini sold 33,600 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the completion of the sale, the insider owned 109,719 shares in the company, valued at $1,587,633.93. The trade was a 23.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 227,641 shares of company stock worth $3,622,515 over the last 90 days. 9.50% of the stock is currently owned by company insiders.

CryoPort Stock Performance

Shares of CYRX stock opened at $15.12 on Friday. CryoPort, Inc. has a fifty-two week low of $7.51 and a fifty-two week high of $16.89. The firm has a market capitalization of $762.05 million, a PE ratio of -16.80 and a beta of 1.89. The stock’s 50-day simple moving average is $15.49 and its 200-day simple moving average is $11.92.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.13%. The firm had revenue of $48.97 million during the quarter, compared to analysts’ expectations of $48.18 million. Sell-side analysts forecast that CryoPort, Inc. will post -0.85 earnings per share for the current year.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

Analysts Set New Price Targets

Several analysts have issued reports on the company. Jefferies Financial Group set a $13.50 target price on CryoPort in a research report on Monday, June 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CryoPort in a research note on Monday, August 3rd. BTIG Research increased their price target on shares of CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Needham & Company LLC lifted their price target on shares of CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.